Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Brand Name :
Synonyms :
Class :
Primary Biliary Cholangitis (Primary Biliary Cirrhosis)Â
The recommended daily dose based on body weight is 10mg/kg
off-label:
In-vivo data suggests intraperitoneal administration of 500 mg/kg for every third day
OATP1B1/1B3 inhibitors increase the concentration of taurursodiol in the serum
OATP1B1/1B3 inhibitors increase the concentration of taurursodiol in the serum
OATP1B1/1B3 inhibitors increase the concentration of taurursodiol in the serum
OATP1B1/1B3 inhibitors increase the concentration of taurursodiol in the serum
OATP1B1/1B3 inhibitors increase the concentration of taurursodiol in the serum
It may diminish the absorption when combined with bile acid sequestrants
OATP1B1/1B3 (SLCO1B1/1B3) inhibitors increase the concentration of taurursodiol in the serum
OATP1B1/1B3 (SLCO1B1/1B3) inhibitors increase the concentration of taurursodiol in the serum
may diminish the concentration of serum when combined with CYP1A2 substrates
may diminish the concentration of serum when combined with CYP1A2 substrates
may diminish the concentration of serum when combined with CYP1A2 substrates
may diminish the concentration of serum when combined with CYP1A2 substrates
may diminish the concentration of serum when combined with CYP1A2 substrates
may enhance the concentration of serum when combined with CYP2C8 substrates
may enhance the concentration of serum when combined with CYP2C8 substrates
may enhance the concentration of serum when combined with CYP2C8 substrates
may enhance the concentration of serum when combined with CYP2C8 substrates
may diminish the concentration of serum when combined with CYP3A4 substrates
may diminish the concentration of serum when combined with CYP3A4 substrates
may diminish the concentration of serum when combined with CYP3A4 substrates
may diminish the concentration of serum when combined with CYP3A4 substrates
may diminish the concentration of serum when combined with CYP3A4 substrates
may have an increasingly adverse effect when combined with taurursodiol
may enhance the concentration of serum when combined with OAT1/3 substrates
may enhance the concentration of serum when combined with OAT1/3 substrates
may enhance the concentration of serum when combined with OAT1/3 substrates
may enhance the concentration of serum when combined with OAT1/3 substrates
may enhance the concentration of serum when combined with OAT1/3 substrates
may have an increasingly adverse effect when combined with taurursodiol
may have an increasingly adverse effect when combined with taurursodiol
may have an increasingly adverse effect when combined with taurursodiol
may have an increasingly adverse effect when combined with taurursodiol
may enhance the serum concentration of OAT1/3 substrates
may enhance the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors
may enhance the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors
may enhance the serum concentration of OAT1/3 Substrates
may enhance the serum concentration of P-glycoprotein/ABCB1 Substrates
may diminish the absorption when combined
aluminum hydroxide/magnesium hydroxideÂ
may decrease the serum concentration of aluminum hydroxide
may diminish the concentration of serum when combined with taurursodiol
may diminish the concentration of serum when combined with taurursodiol
may diminish the concentration of serum when combined with taurursodiol
may diminish the concentration of serum when combined with taurursodiol
may diminish the concentration of serum when combined with taurursodiol